期刊文献+

弥漫大B细胞淋巴瘤中miR-5585-3p的表达及其意义 被引量:5

Expression of miR-5585-3p in diffuse large B-cell lymphoma and its prognostic significance
下载PDF
导出
摘要 目的 探讨miR-5585-3p在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达与临床病理特征的相关性及其预后意义。方法 选取12例DLBCL石蜡标本进行基因芯片扫描,依据foldchange≥1.5、P≤0.05筛选出差异性表达的miRNAs,miR-5585-3p是其中之一。采用qRT-PCR检测95例DLBCL石蜡标本中miR-5585-3p的表达,15例淋巴结反应性增生组织作为对照,并结合患者临床病理学资料进行分析。结果 miR-5585-3p在DLBCL中的表达量显著高于淋巴结反应性增生组织(P〈0.001),且non-GCB亚型miR-5585-3p的表达水平是GCB型的2.4倍(P=0.006)。miR-5585-3p高表达与淋巴瘤国际预后指数(IPI)呈正相关(P=0.005)。Kaplan-Meier生存分析显示:DLBCL中高表达miR-5585-3p的患者生存率明显低于miR-5585-3p低表达者(P=0.049)。预后多因素Cox分析显示,年龄〉60岁(P=0.010)、IPI评分3~5分(P=0.004)、高表达miR-5585-3p(P=0.014)为DLBCL独立不良预后指标。结论 miR-5585-3p高表达可能与DLBCL不良预后有关。 Purpose To investigate the expression of miR-5585-3p in diffuse large B-cell lymphoma (DLBCL) and its relevance with clinical pathological features, prognostic significance in clinical practice. Methods Altered expression of miRNAs was identified by microarray in an initial 12 DLBCL cases by using fold change ≥ 1.5, P≤0.05 as cutoff value, miR-5585-3p was one of them. The miR-5585-3p expression was confirmed by qRT-PCR in 95 DLBCL samples and 15 samples of reactive hyperplasia as controls. The clinical pathological data of patients were analyzed with the miR-5585-3p expression. Results The expression level of miR-5585-3p was significantly higher in DLBCL patients than in reactive hyperplasia samples ( P 〈 0. 001 ) , and the expression of miR-5585-3p in non-GCB was 2.4 times as much as that in GCB subtypes (P =0. 006). Positive correlation was observed between the rniR-5585-3p expression level and IPI score ( P = 0. 005 ). Kaplan-Meier analysis showed that higher expression level of miR-5585-3p was signifi- cantly associated with a poorer overall survival compared with lower expression of miR-5585-3p in DLBCL patients ( P = 0. 049). Mult- ivariahle Cox regression revealed the age 〉60 (P =0. 010) , IPI score 3-5 (P =0. 004) , higher expression miR-5585-3p (P =0. 014) were independent poor prognostic factors of DLBCL. Conclusion The higher expression of miR-5585-3p in DLBCL might be relative to the poor prognosis of DLBCL.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2016年第2期152-156,共5页 Chinese Journal of Clinical and Experimental Pathology
基金 安徽省自然科学基金(1608085MH228) 杨森科学研究基金(JRCC2012肿瘤01)
关键词 弥漫大B细胞淋巴瘤 miR-5585-3p 预后 diffuse large B-cell lymphoma miR-5585-3p prognosis
  • 相关文献

参考文献26

  • 1Campo E, Swerdlow S H, Harris N L, et al. The 2008 WHO clas- sification of lymphoid neoplasms and beyond: evolving concepts and practical applications [ J ]. Blood, 2011,117 ( 19 ) :5019 - 32.
  • 2Wu Z, Wu Q, Wang C, et al. MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomar- ker for breast cancer prognosis [ J ]. BMC Cancer, 2010,10 (6) : 542 -51.
  • 3Sehn L H, Berry B, Chhanabhai M, et al. The revised Interna- tional Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lympho- ma treated with R-CHOP [ J ]. Blood, 2007,109 (5) : 1857 - 61.
  • 4Zhou Z, Sehn L H, Rademaker A W, et al. An enhanced intema- tional prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[ J]. Blood, 2014, 123(6) :837 -42.
  • 5Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas : a randomised controlled trial (RICOVER-60) [ J ]. Lancet Oncol, 2008,9 ( 1 ) : 105 - 16.
  • 6De Jong D, Rosenwald A, Chhanabhai M, et al. Immunohisto- chemical prognostic markers in diffuse large B-cell lymphoma: val- idation of tissue microarray as a prerequisite for broad clinical ap- plications-a study from the lunenburg lymphoma biomarker con- sortium[ J]. J Clin Oncol, 2007,25(7):805 -12.
  • 7Tang G. siRNA and miRNA: an insight into RISCs[ J]. Trends Biochem Sci, 2005,30(2) :106 - 14.
  • 8Vasilatou D, Papageorgiou S, Pappa V, et al. The role of microR- NAs in normal and malignant hematopoiesis [ J ]. Eur J Haematol, 2010,84(1) :1 - 16.
  • 9Kloosterman W P, Plasterk R H. The diverse functions of microR- NAs in animal development and disease [ J ]. Dev Cell, 2006,11 (4) :441 -50.
  • 10Lawrie C H, Gal S, Dunlop H M, et al. Detection of elevated lev- els of tumour-associated microRNAs in serum of patients with dif- fuse large B-cell lymphoma[ ]]. Br J Haematol, 2008,141 (5) : 672 - 5.

二级参考文献44

  • 1朱雄增.弥漫性大B细胞淋巴瘤研究进展[J].临床与实验病理学杂志,2005,21(3):262-265. 被引量:16
  • 2Hans C P, Weisenburger D D, Greiner T C, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by im- munohistochemistry using a tissue microarray [ J]. Blood, 2004, 103(1) :275 -82.
  • 3Lopez-Guillermo A, Colomo L, Jimrnez M, et al. Diffuse large B- cell lymphoma: clinical and biological characterization and out- come according to the nodal or extranodal primary origin [ J ]. J Clin Oncol, 2005,23 ( 12 ) :2797 - 804.
  • 4Park S K, Yun J, KimS H, et al. A controversial conclusion re- garding primary extranodal diffuse large B-ceil lymphoma[ J]. Ko- rean J Hematot, 2011,46(3) :207 -8.
  • 5Harris N L, Jaffe E S, Stein H, et al. A revised European-Ameri- can classification of lymphoid neoplasms: a proposal from the in- ternational lymphoma study group [J]. Blood, 1994,84 ( 5 ) : 1361 -92.
  • 6Ko Y H, Kim C W, Park C S, et al. REAL classification of ma- lignant lymphomas in the Republic of Korea : incidence of recently recognized entities and changes in clinicopathologic features: He- matolymphoreticular Study Group of the Korean Society of Patholo- gists. Revised European-American lymphoma[J]. Cancer, 1998, 83(1) :806 -12.
  • 7d' Amore F, Brincker H, Gronbaek K, et al. Non-Hodgkin' s lymphoma of the gastrointestinal tract : a population-based analysis of incidence, geographic distribution, clinicopathologic presenta- tion features, and prognosis. Danish Lymphoma Study Group[ J]. J Clin Oncol, 1994,12(8) :1673 -84.
  • 8Nakamura S, Matsumoto T, Lida M, et al. Primary gastrointesti- nal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends [ J ]. Cancer, 2003,97 (10) :2462 - 73.
  • 9Mihaljevic B, Nedeljkov-Jancic R, Vujicic V, et al. Primary ex- tranodal lymphomas of gastrointestinal localizations : a single insti- tution 5-yr experience [ J ]. Med Oncol, 2006,23 (2) :225 - 35.
  • 10Ibrahim E M, Ezzat A A, E1-Weshi A N, et al. Primary intestinal diffuse large B-cell non-Hodgkin' s lymphoma: clinical features, management, and prognosis of 66 patients[J]. Ann Oncol, 2001, 12(1) :53 -8.

共引文献22

同被引文献40

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部